Sugi Predict

Sugi Predict / Compounds / SCHEMBL147388

SCHEMBL147388

SCHEMBL147388

CC(C)(C)OC(=O)c1cc(Br)ccc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.54
▸ HPGD P15428 4/20 0.51
▸ THRB P10828 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ MAPT P10636 4/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ POLB P06746 2/20 0.45
▸ GAA P10253 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ CYP1A2 P05177 1/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ GPR55 Q9Y2T6 1/20 0.44
▸ KMT2A Q03164 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5985839 0.89 ALDH1A1 (0.48) ALDH1A1HPGDTHRBHTTMAPT
SCHEMBL14321549 0.87 AAK1 (0.43) ALDH1A1HPGDRAB9ANPC1SMN1; SMN2
SCHEMBL4628583 0.84 CES2 (0.41) ALDH1A1HPGDGAARECQLCYP1A2
SCHEMBL27299076 0.84 ALDH1A1 (0.51) ALDH1A1HPGDTHRBHTTMAPT
SCHEMBL7860222 0.83 PTPN2 (0.50) ALDH1A1HPGDHTTMAPTPOLB
SCHEMBL7858859 0.83 ALDH1A1 (0.53) ALDH1A1HPGDHTTMAPTTDP1
SCHEMBL8143660 0.81 HPGD (0.56) ALDH1A1HPGDHTTMAPTPOLB
SCHEMBL1605808 0.81 MAPT (0.43) ALDH1A1HPGDMAPTRECQLCYP1A2
SCHEMBL195401 0.81 HPGD (0.60) ALDH1A1HPGDTHRBHTTMAPT
SCHEMBL29849280 0.81 HPGD (0.60) ALDH1A1HPGDTHRBHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595239-B2 Substituted isoxazoline derivatives BASF SE (DE) 2026-04-07 — — US disclosed
EP-4291551-B1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2025-08-13 — — EP disclosed
US-20240140917-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2024-05-02 — — US disclosed
EP-4291551-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2023-12-20 — — EP disclosed
CN-116888101-A Substituted isoxazoline derivatives 巴斯夫欧洲公司 2023-10-13 — — CN disclosed
WO-2022171472-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2022-08-18 — — WO disclosed
EP-4043444-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2022-08-17 — — EP disclosed
EP-3325465-B1 PESTICIDALLY ACTIVE PYRAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2022-05-18 — — EP disclosed
EP-3325465-B1 PESTICIDALLY ACTIVE PYRAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2022-05-18 — — EP disclosed
EP-3251679-B1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER MITSUBISHI TANABE PHARMA CORP (JP) 2020-12-16 — — EP disclosed
EP-1651658-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER TANABE SEIYAKU CO., LTD. (JP) 2006-05-03 — — EP disclosed
US-20050256180-A1 Substituted pyrazolyl compounds for the treatment of inflammation BERGMANIS ARIJA A 2005-11-17 — — US disclosed
US-20050233988-A1 Novel compounds TANABE SEIYAKU CO., LTD. (JP) 2005-10-20 — — US disclosed
US-6956052-B2 Substituted pyrazolyl compounds for the treatment of inflammation PHARMACIA CORPORATION (US) 2005-10-18 — — US disclosed
WO-2005012326-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER TANABE SEIYAKU CO., LTD. (JP) 2005-02-10 — — WO disclosed
EP-1501805-A1 SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2005-02-02 — — EP disclosed
EP-1444207-A2 SUBSTITUTED PYRAZOLYL-COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2004-08-11 — — EP disclosed
US-20040110741-A1 Substituted pyrazolyl compounds for the treatment of inflammation PHARMACIA CORPORARTION 2004-06-10 — — US disclosed
WO-2003095430-A1 SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2003-11-20 — — WO disclosed
WO-2003024935-A2 SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2003-03-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050233988-A1 Novel compounds CYP1B1, CYP4B1, CYP2B6 ALDH1A1 831/4885HPGD 391/4885THRB 3054/4885
US-12595239-B2 Substituted isoxazoline derivatives CBR3, ADRA2C, CYP4Z1 ALDH1A1 854/4885HPGD 4809/4885THRB 2268/4885
US-20040110741-A1 Substituted pyrazolyl compounds for the treatment of inflammation IRAK4, IL1B, IRAK2 ALDH1A1 897/4885HPGD 402/4885THRB 3046/4885
US-20240140917-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES CYP4X1, PRDX5, PRDX1 ALDH1A1 1168/4885HPGD 2526/4885THRB 3711/4885
US-20050256180-A1 Substituted pyrazolyl compounds for the treatment of inflammation IRAK4, IL1B, IRAK2 ALDH1A1 897/4885HPGD 402/4885THRB 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.